FORM 4

# **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

| _      |    |             |    |        |       |
|--------|----|-------------|----|--------|-------|
| $\sim$ | MR | $\Lambda D$ | 00 | $\cap$ | / N I |
|        |    |             |    |        |       |

| OMB Number:              | 3235-0287 |
|--------------------------|-----------|
| Estimated average burder | 1         |
| hours per response:      | 0.5       |

#### Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Name and Address of Reporting Person*     Ben Yong |                         |  | 2. Issuer Name and Ticker or Trading Symbol Corbus Pharmaceuticals Holdings, Inc. [ CRBP ]                                                                                                                       | Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director 10% Owner |                                                         |                       |  |  |  |
|----------------------------------------------------|-------------------------|--|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|---------------------------------------------------------|-----------------------|--|--|--|
| (Last)                                             | (Last) (First) (Middle) |  | 3. Date of Earliest Transaction (Month/Day/Year) 05/18/2023                                                                                                                                                      |                                                                                               | Officer (give title below)                              | Other (specify below) |  |  |  |
| 500 RIVER RIDGE DRIVE                              |                         |  | f Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applic                                                                                                          |                                                                                               |                                                         |                       |  |  |  |
| (Street)<br>NORWOOD                                | MA                      |  |                                                                                                                                                                                                                  | X                                                                                             | Form filed by One Reporting Form filed by More than One |                       |  |  |  |
| - MIN                                              |                         |  | Rule 10b5-1(c) Transaction Indication                                                                                                                                                                            |                                                                                               |                                                         |                       |  |  |  |
| (City) (State) (Zip)                               |                         |  | Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. |                                                                                               |                                                         |                       |  |  |  |

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction<br>Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | , Transaction Code (Instr. 8) |   | 4. Securities Acquired (A) or<br>Disposed Of (D) (Instr. 3, 4 and 5) |               |       | Following Reported              | 6. Ownership<br>Form: Direct (D)<br>or Indirect (I)<br>(Instr. 4) | Beneficial<br>Ownership |
|---------------------------------|--------------------------------------------|-------------------------------------------------------------|-------------------------------|---|----------------------------------------------------------------------|---------------|-------|---------------------------------|-------------------------------------------------------------------|-------------------------|
|                                 |                                            |                                                             | Code                          | v | Amount                                                               | (A) or<br>(D) | Price | Transaction(s) (Instr. 3 and 4) |                                                                   | (Instr. 4)              |

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security (Instr.<br>3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 4.<br>Transac<br>Code (Ir<br>8) |   |       |     | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |                    | 7. Title and Amount of<br>Securities Underlying<br>Derivative Security (Instr.<br>3 and 4) |                                     | Derivative | Reported                     |   | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|-----------------------------------------------------|-----------------------------------------------------------------------|--------------------------------------------|-------------------------------------------------------------|---------------------------------|---|-------|-----|----------------------------------------------------------------|--------------------|--------------------------------------------------------------------------------------------|-------------------------------------|------------|------------------------------|---|--------------------------------------------------------------------|
|                                                     |                                                                       |                                            |                                                             | Code                            | v | (A)   | (D) | Date<br>Exercisable                                            | Expiration<br>Date | Title                                                                                      | Amount<br>or<br>Number<br>of Shares |            | Transaction(s)<br>(Instr. 4) |   |                                                                    |
| Stock Option<br>(right to buy)                      | \$9.96                                                                | 05/18/2023                                 |                                                             | A                               |   | 5,300 |     | (1)                                                            | 05/18/2033         | Common<br>Stock                                                                            | 5,300                               | \$0.00     | 5,300                        | D |                                                                    |

## Explanation of Responses:

1. The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest 100% on the one year anniversay from the date of grant.

#### Remarks:

/s/ Sean Moran, attorney-in-fact for Yong Ben

\*\* Signature of Reporting Person Dat

05/22/2023

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.